OmniAb to Showcase AI-Powered Antibody Discovery Platform at Upcoming Investor Conferences

OmniAb Announces Participation in Key Investor Conferences

OmniAb, Inc. (NASDAQ: OABI), a leading biotech company specializing in antibody discovery, has announced its participation in two significant investor conferences this November 1

1

2

2

. This move underscores the company's commitment to engaging with the investment community and showcasing its innovative technology platform.

Conference Details and Management Participation

The company will be represented at two high-profile events:

1. Stifel 2024 Healthcare Conference (November 18-19, Lotte New York Palace Hotel):

   • Kurt Gustafson, Chief Financial Officer, will engage in one-on-one meetings with investors on November 19th 1

     1

     .

2. Jefferies London Healthcare Conference (November 19-21, Waldorf Hilton):

   • Matt Foehr, Chief Executive Officer, will participate in one-on-one and small-group meetings with investors on November 19-20 1

     1

     .

These conferences provide OmniAb with a platform to discuss its cutting-edge discovery research technology and its potential impact on the pharmaceutical and biotech industries.

OmniAb's Innovative Technology Platform

At the core of OmniAb's offerings is its proprietary technology platform, which leverages Biological Intelligence™ (BI) to revolutionize antibody discovery 1

1

2

2

. This platform is designed to:

1. Create and screen diverse antibody repertoires
2. Quickly identify optimal antibodies and target-binding proteins
3. Facilitate the development of next-generation therapeutics

The company's suite of technologies includes:

• Proprietary transgenic animals (OmniRat®, OmniChicken®, OmniMouse®)
• Specialized platforms for bispecific antibodies (OmniFlic®, OmniClic®)
• Unique antibody discovery tools (OmniTaur™, OmnidAb™)
• AI and machine learning integration (OmniDeep™)

Applications and Potential Impact

OmniAb's technology can be applied to discover various next-generation antibody-based therapeutic modalities, including:

• Bi- and multi-specific biologics
• Antibody-drug conjugates
• CAR-T therapies
• Targeted radiotherapeutics

The company's focus on ion channels and transporters further differentiates its technology, creating opportunities in emerging target classes 1

1

2

2

.

Industry Significance

OmniAb's participation in these investor conferences highlights the growing importance of AI-driven technologies in drug discovery and development. As the biotech industry continues to evolve, platforms like OmniAb's that combine biological expertise with advanced computational methods are likely to play an increasingly crucial role in shaping the future of therapeutic development.